Zealand Pharma's Annual General Meeting 2023
Company announcement – No. 9 / 2023
Zealand Pharma's Annual General Meeting 2023
Copenhagen, March 29, 2023 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2023 as a partly electronic general meeting.
At the meeting, all proposals presented to the General Meeting were adopted.
The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2022 was approved. The meeting also approved that the financial result for 2022, which was a loss of TDKK 1,202,135, was carried forward to the next financial year.
All the incumbent board members were re-elected as recommended by the Nomination Committee. Hence, Zealand's Board of Directors consists of the following members:
- Alf Gunnar Martin Nicklasson
- Kirsten Aarup Drejer
- Alain Munoz
- Jeffrey Berkowitz
- Michael John Owen
- Leonard Kruimer
- Bernadette Mary Connaughton
After the Annual General Meeting, the Board of Directors constituted itself with Martin Nicklasson and Kirsten Aarup Drejer continuing as the Chair and the Vice-Chair, respectively.
The Audit Committee will comprise Martin Nicklasson, Leonard Kruimer, Bernadette Mary Connaughton and Jeffrey Berkowitz, with Leonard Kruimer chairing the Committee. Martin Nicklasson, Michael J. Owen and Alain Munoz, with Martin Nicklasson as the Chair, will continue to comprise the Remuneration Committee, while the Scientific Committee will continue to comprise Kristen Aarup Drejer, Alain Munoz and Michael J. Owen, with Kirsten Aarup Drejer chairing the Committee.
EY Godkendt Revisionspartnerselskab was re-elected as Zealand's auditor as proposed by the Board of Directors in accordance with the recommendation of the Audit Committee.
The Board of Directors was authorized to allow Zealand to acquire, in the period until the next Annual General Meeting, treasury shares directly for a nominal value of up to 10% of Zealand's share capital from time to time.
Zealand's new Remuneration Policy and the Remuneration Report presented under agenda items 7 and 8, respectively, were approved by the General Meeting as proposed by the Board of Directors.
The fees for the Board of Directors for the financial year 2023 presented under agenda item 9 were approved by the General Meeting. The fees remain unchanged compared to 2022.
The Board of Directors was authorized to increase the share capital of Zealand during the period until 29 March 2028 by way of cash contribution up to an aggregate amount of nominally DKK 10,340,419 at market price and without pre-emption rights for the existing shareholders. The new authorization will replace the existing authorization set forth in Article 7.1 of the Company's Articles of Association.
Finally, the existing authorization for the Board of Directors to issue warrants during the period until 6 April 2027 with a right to subscribe for shares in the Company up to an aggregate amount of nominally DKK 2,181,707 without pre-emption rights for existing shareholders pursuant to Articles 8.10-8-12 of the Company's Articles of Association was extended by one year to 29 March 2028 and increased by nominally DKK 925,772. The total number of warrants available for issuance under this authorization is hereinafter 2,210,489.
Zealand Pharma A/S
The Board of Directors
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly.
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AKVA group ASA: New Land Based contract signed6.6.2023 11:08:00 CEST | Press release
AKVA is pleased to announce the award of a new RAS contract with Cermaq Norway for the 12 million post smolt facility at Sørøya in Finnmark. The estimated contract value is minimum EUR 60 million. Engineering and design work will start immediately. Knut Nesse, CEO of AKVA: “This contract with Cermaq Norway represents for AKVA the largest contract in Norway ever, and will support the activity level in our Land Based business for the next few years”. Dated: 6 June 2023 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:email@example.com Ronny MeinkøhnChief Financial OfficerPhone:+47 51 77 85 00Mobile:+47 98 20 67 76E-mail:firstname.lastname@example.org *** This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements according to section 5-12 of the Norwegian Securities Trading Act. The information was submitted for publication by
DSV, 1037 - SHARE BUYBACK IN DSV A/S6.6.2023 11:01:53 CEST | Press release
Company Announcement No. 1037 On 27 April 2023, we initiated a share buyback programme, as described in Company Announcement No. 1031. According to the programme, the company will in the period from 27 April 2023 until 24 July 2023 purchase own shares up to a maximum value of DKK 4,500 million, and no more than 5,000,000 shares, corresponding to 2.28% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-19937,6391,310.771,229,030,13420:30 May 202361,5321,350.7083,111,23521:31 May 202361,0971,343.4182,078,38922:1 June 202380,7471,343.36108,472,20123:2 June 202380,7101,362
Transactions in connection with share buyback programme6.6.2023 11:00:00 CEST | Press release
On 27 April 2022, Tryg A/S (“Tryg”) announced that a share buyback programme of DKK 5.0 billion had been initiated as a result of the sale of Codan Denmark. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 03 July 2023. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 30 May 2023 to 02 June 2023: Number of sharesAvg. purchase price, DKKTransaction value, DKK30 May 2023 40,000 159.74 6,389,60031 May 2023 50,000 158.86 7,943,00001 June 2023 50,000 157.98 7,899,00002 June 2023 70,000 157.74 11,041,800Accumulated for the period210,000-33,273,400Accumulated under the programme30,434,000-4,861,506,740 Detailed information
Kitron: Ny aksjekapital registrert6.6.2023 10:58:43 CEST | Pressemelding
(2023-06-06) Det vises til børsmelding fra Kitron ASA 1. juni 2023 vedrørende utstedelse av 526 081 nye aksjer under Selskapets aksjeinsentivprogram. Kapitalforhøyelsen i forbindelse med aksjeinsentivprogrammet har i dag blitt registrert i Foretaksregisteret. Registrert aksjekapital i Kitron ASA etter registreringen er NOK 19 821 713,40 fordelt på 198 217 134 aksjer hver pålydende NOK 0.10. Hver aksje gir én stemme på Selskapets generalforsamling. Kitron er et ledende skandinavisk foretak innen produksjon av elektronikk og relaterte tjenester for sektorene Konnektivitet, Elektrifisering, Industri, Medisinsk utstyr og Forsvar/Luftfart. Konsernet har virksomhet i Norge, Sverige, Danmark, Litauen, Tyskland, Polen, Tsjekkia, India, Kina og USA. Kitron har rundt 3 200 ansatte, og driftsinntektene var EUR 641 million i 2022. www.kitron.com (http://www.kitron.com) Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.
Kitron: New share capital registered6.6.2023 10:58:43 CEST | Press release
(2023-06-06) Reference is made to the stock exchange announcement from Kitron ASA on 1 June 2023 regarding issuance of 526,081 new shares under the Company's share incentive program. The share capital increase in connection with the share incentive program has been registered in the Norwegian Register of Business Enterprises today. Registered share capital in Kitron ASA following the registration is NOK 19,821,713.40 divided on 198,217,134 shares, each with a par value of NOK 0.10. Each share gives one vote at the company's general meeting. Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group is located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China and the United States. Kitron has about 3 200 employees, and revenues were EUR 641 million in 2022. www.kitron.com (http://www.kitron.com) This information is subject to t